According to filings with the U.S. Securities and Exchange Commission, Sonavex is raising up to $15 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Sonavex
Sonavex is a medical device company that provides automated 3D ultrasound solutions designed for the dialysis access care team, enabling clinicians to quantify and visualize critical clinical data to improve patient care. The company focuses on empowered patient care by delivering actionable visual and quantitative vascular information directly at the point of care, helping inform treatment decisions and support superior clinical outcomes while reducing costs for the healthcare system. Its patented products, including the first-ever ultrasound marker designed specifically for blood vessels, are engineered to easily collect accurate data in a variety of settings and to be usable by any member of the care team, not just ultrasound specialists. Sonavex emphasizes a mission-driven culture dedicated to empowering clinicians, improving patient outcomes, and delivering savings to the healthcare system through novel and automated ultrasound technology. Through these innovations, Sonavex positions itself as a leader in advanced vascular ultrasound solutions that integrate seamlessly into routine dialysis and vascular access care workflows to enhance both clinical and economic value.

To learn more, visit https://www.sonavex.com/
LinkedIn: https://www.linkedin.com/company/sonavex

Contact:
David Narrow, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.